Effect of gender difference on platelet reactivity
Nicoline J. Breet,M. A. Sluman,M. A. J. P. J. van Berkel,J. W. Van Werkum,Heleen J. Bouman,Ankie M. Harmsze,Johannes C. Kelder,Freek J. Zijlstra,Christian M. Hackeng,J. M. ten Berg +9 more
TLDR
Although the magnitude of platelet reactivity was higher in women, the absolute difference between genders was small and both the cut-off value to identify patients at risk and the incidence of the composite endpoint were similar between genders.Abstract:
Background
Previous studies have suggested that women do not accrue equal therapeutic benefit from antiplatelet medication as compared with men. The physiological mechanism and clinical implications behind this gender disparity have yet to be established.read more
Citations
More filters
Journal ArticleDOI
Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome
Ahmed Haider,Susan Bengs,Judy M. Luu,Elena Osto,Jolanta M. Siller-Matula,Jolanta M. Siller-Matula,Taulant Muka,Catherine Gebhard,Catherine Gebhard +8 more
TL;DR: Current evidence for gender and sex differences in vascular biology, clinical presentation, and outcomes of acute coronary syndrome is summarized and potential mechanisms and non-traditional risk conditions modulating the course of disease in women and men are discussed.
Journal ArticleDOI
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A ‘state-of-the-art’ paper
Giuseppe Patti,Raffaele De Caterina,Rosanna Abbate,Felicita Andreotti,Luigi M. Biasucci,Paolo Calabrò,Gabriele Cioni,Giovanni Davì,Germano Di Sciascio,Enrica Golia,Paolo Golino,Gelsomina Malatesta,Fabio Mangiacapra,Rossella Marcucci,Annunziata Nusca,Vito Maurizio Parato,Vittorio Pengo,Domenico Prisco,Fabio M. Pulcinelli,Giulia Renda,Elisabetta Ricottini,Benedetta Ruggieri,Francesca Santilli,Francesco Sofi,Marco Zimarino +24 more
TL;DR: Suggestions on current indications of antiplatelet therapy for cardiovascular prevention in women with different clinical features are provided; no strong recommendation may be given because the available data derive from observational studies or post hoc/subgroup analyses of randomized studies without systematic adjustments for baseline risk profiles.
Journal ArticleDOI
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
M. Verdoia,Patrizia Pergolini,Roberta Rolla,Matteo Nardin,A. Schaffer,Lucia Barbieri,Paolo Marino,Giorgio Bellomo,H. Suryapranata,G. De Luca +9 more
TL;DR: In patients receiving dual antiplatelet therapy, advanced age is independently associated with a reduced effectiveness of ADP antagonists and a higher rate of HRPR with both clopidogrel and ticagrelor.
Journal ArticleDOI
The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function.
Olivia A. Lin,Zubair A. Karim,Hari Priya Vemana,Enma Veronica Paez Espinosa,Fadi T. Khasawneh +4 more
TL;DR: The data indicate that the antidepressant 5-HT2A antagonists, cyproheptadine and pizotifen do exert antiplatelet and thromboprotective effects, but similar to clopidogrel and EMD 281014, their use may interfere with normal hemostasis.
Journal ArticleDOI
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials
Emily S. Lau,Eugene Braunwald,Sabina A. Murphy,Stephen D. Wiviott,Marc P. Bonaca,Steen Husted,Stefan James,Lars Wallentin,Peter Clemmensen,Matthew T. Roe,E. Magnus Ohman,Robert A. Harrington,Jessica L. Mega,Deepak L. Bhatt,Marc S. Sabatine,Michelle L. O'Donoghue +15 more
TL;DR: In randomized trials, the efficacy and safety of the potent P2Y12 inhibitors were comparable between men and women, and sex should not influence patient selection for the administration of potent P3y12 inhibitors.
References
More filters
Journal ArticleDOI
Heart Disease and Stroke Statistics—2010 Update A Report From the American Heart Association
Donald M. Lloyd-Jones,Robert J. Adams,Todd M. Brown,Mercedes R. Carnethon,Shifan Dai,Giovanni de Simone,T. Bruce Ferguson,Earl S. Ford,Karen L. Furie,Cathleen Gillespie,Alan S. Go,Kurt J. Greenlund,Nancy Haase,Susan M. Hailpern,P. Michael Ho,Virginia J. Howard,Brett M. Kissela,Steven J. Kittner,Daniel T. Lackland,Lynda D. Lisabeth,Ariane Marelli,Mary M. McDermott,James B. Meigs,Dariush Mozaffarian,Michael E. Mussolino,Graham Nichol,Véronique L. Roger,Wayne D. Rosamond,Ralph L. Sacco,Paul D. Sorlie,Randall S. Stafford,Thomas Thom,Sylvia Wasserthiel-Smoller,Nathan D. Wong,Judith Wylie-Rosett +34 more
TL;DR: The Statistical Update brings together the most up-to-date statistics on heart disease, stroke, other vascular diseases, and their risk factors and presents them in its Heart Disease and Stroke Statistical Update each year.
Journal ArticleDOI
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data
Alan D. Lopez,Colin Mathers,Majid Ezzati,Dean T. Jamison,Dean T. Jamison,Christopher J L Murray +5 more
TL;DR: Despite uncertainties about mortality and burden of disease estimates, the findings suggest that substantial gains in health have been achieved in most populations, countered by the HIV/AIDS epidemic in Sub-Saharan Africa and setbacks in adult mortality in countries of the former Soviet Union.
Journal ArticleDOI
Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions
Donald E. Cutlip,Stephan Windecker,Roxana Mehran,Ashley B Boam,David J. Cohen,Gerrit-Anne van Es,P. Gabriel Steg,Marie-Angèle Morel,Laura Mauri,Pascal Vranckx,Eugene P. McFadden,Alexandra J. Lansky,Martial Hamon,Mitchell W. Krucoff,Patrick W. Serruys +14 more
TL;DR: Criteria for assessment of death, myocardial infarction, repeat revascularization, and stent thrombosis were developed and provide consistency across studies that can facilitate the evaluation of safety and effectiveness of these devices.
Journal ArticleDOI
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Steven R. Steinhubl,Peter B. Berger,J. Tift Mann,Edward T.A. Fry,Augustin DeLago,Charles Wilmer,Eric J. Topol +6 more
TL;DR: Following PCI, long-term clopidogrel therapy significantly reduced the risk of adverse ischemic events and subgroup analyses suggest that longer intervals between the loading dose and PCI may reduce events.
Journal ArticleDOI
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
TL;DR: In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.